



# Prevent coke buildup / Increase PDH unit efficiency

DMDS Evolution® E2 is the leading sulfur-based, coke suppression and metallurgy protection technology that is used globally in Propane and Butane DeHydrogenation units. Hydrocarbons exposed to elevated temperatures form coke, which can cause metal carburization and affect heat transfer and flow dynamics. In less than 15 minutes, enough coke is formed to require PDH and BDH unit shutdown and immediate cleaning and decoking.

DMDS Evolution® E2 injection prevents coke from forming in hot areas of the PDH process, so your units can continue running efficiently and effectively.

+40

Arkema has the largest worldwide production capacity with over 40 years of experience producing highpurity DMDS

### **Benefits of DMDS Evolution® E2**


- → Protects your PDH units and allows them to be online longer
- \* Provides the needed passivation against coking when used in low quantities (<100 ppm)
- → Delivers a better scent than standard DMDS, improving the user experience
- 👺 Approved by Major Technology Licensors as the only sulfur compound for PDH and BDH units

600°C


DMDS Evolution® E2 decomposes completely by 600°C, enabling the formation of a protective layer of sulfur to prevent coke formation in your installation


### Composition

Appearance	Clear liquid
DMDS content	> 99.5%
Methyl Mercaptan content	< 0.01%
Water content	< 600 ppmw
Fragrance	< 0.3%
- C/H/O atoms	65/8/27 wt. %
- N atom	None









## Delivers an optimal release of H<sub>2</sub>S


At 400°C, DMDS Evolution® E2 starts to release H<sub>2</sub>S and decomposes completely by 600°C. The decomposition of our product enables the formation of a protective layer of sulfur to prevent coke formation in your installation.

# Your partnership with Arkema, the worldwide DMDS supplier

Arkema has the largest worldwide production capacity with over 40 years of experience producing high-purity DMDS. Multiple production sites and strategically placed global distribution and bulk storage facilities ensure a fast and reliable worldwide supply to help you maintain profitability. DMDS and DMDS Evolution® E2 production is ISO 9001-and ISO 14001-certified.

#### **About Arkema**

A global chemical company and France's leading chemicals producer, Arkema is building the future of the chemical industry every day. Deploying a responsible, innovation-based approach, we produce state-of-the-art specialty chemicals that provide customers with practical solutions to such challenges as climate change, access to drinking water, the future of energy,



fossil fuel preservation and the need for lighter materials. With operations in nearly 50 countries, 19,000 employees, and research centers in North America, France and Asia, Arkema generates pro forma annual revenue of €7.5 billion and holds leadership positions in all its markets with a portfolio of internationally recognized brands.

Mo-SH

HC

CS<sub>2</sub>
0 600 700 800 900

ATURE (°C)

The need for lighter in nearly 50 as, and research ance and Asia, annual revenue dership positions olio of rands.

The statements, technical information and recommendations contained herein are believed to be accurate as of the date hereof. Since the conditions and methods of use of the product and of the information referred to herein are beyond our control, Arkema expressly disclaims any and all liability as to any results obtained or arising from any use of the product or reliance on such information; NO WARRANTY OF FITNESS FOR ANY PARTICULAR PURPOSE, WARRANTY OF MERCHANTABILITY OR ANY OTHER WARRANTY, EXPRESSED OR IMPLIED, IS MADE CONCERNING THE GOODS DESCRIBED OR THE INFORMATION PROVIDED HEREIN. The information provided herein relates only to the specific product designated and may not be applicable when such product is used in combination with other materials or in any process. The user should thoroughly test any application before commercialization. Nothing contained herein constitutes a license to practice under any patent and it should not be construed as an inducement to infringe any patent and the user is advised to take appropriate steps to be sure that any proposed use of the product will not result in patent infringement. See SDS for Health & Safety Considerations. Arkema has implemented a MedicalPolicy regarding the use of Arkema products in medical devices applications that are in contact with the body or circulating bodily fluids (http://www.arkema.com/en/social-responsibility/index) and the latest applications of the latest applications ofresponsible-product-management/medical-device-policy/index.html). Arkema has designated medical grades to be used for such medical device applications. Products that have not been designated as medical grades are not authorized by Arkema for use in medical device applications that are in contact with the body or circulating bodily fluids. In addition, Arkema strictly prohibits the use of any Arkema products in medical device applications that are implanted in the body or in contact with bodily fluids or tissues for greater than 30 days. The Arkema trademarks and the Arkema name shall not be used in conjunction with customers' medical devices, including without limitation, permanent or temporary implantable devices, and customers shall not represent to anyone else, that Arkema allows, endorses or permits the use of Arkema products in such medical devices. It is the sole responsibility of the manufacturer of the medical device to determine the suitability (including biocompatibility) of all raw materials, products and components, including any medical grade Arkema products, in order to ensure that the final end-use product is safe for its end use; performs or functions as intended; and complies with all applicable legal and regulatory requirements (FDA or other national drug agencies). It is the sole responsibility of the manufacturer of the medical device to conduct all necessary tests and inspections and to evaluate the medical device under actual end-use requirements and to adequately advise and warn purchasers, users, and/or learned intermediaries (such as physicians) of pertinent risks and fulfill any postmarket surveillance obligations. Any decision regarding the appropriateness of a particular Arkema material in a particular medical device should be based on the judgment of the manufacturer, seller, the competent authority, and the treating physician. DMDS Evolution is a registered trademark of Arkema



Headquarters: Arkema France

420, rue d'Estienne d'Orves 92705 Colombes Cedex – France Tel.: +33 (0)1 49 00 80 80 Fax: +33 (0)1 49 00 83 96

arkema.com

© 2016 Arkema Inc. All rights reserved.